Morgan Stanley lowered the firm’s price target on Baxter (BAX) to $27 from $28 and keeps an Underweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter price target lowered to $32 from $34 at Citi
- Baxter appoints Andrew Hider as CEO
- Baxter International Appoints Andrew Hider as New CEO
- Baxter International Amends Credit and Loan Agreements
- Baxter International Poised for Growth: Buy Rating Affirmed Amid Strategic Initiatives and Promising Outlook